ArticleNature medicine2022
Long-term neurologic outcomes of COVID-19.
Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 311 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
311 citing papers in PubMed, 4 syntheses or guidelines pooled it, 502 citations in OpenAlex.
- Associated thromboembolic events to the post COVID syndrome: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- A dual-database bibliometric analysis of post-COVID-19 condition and cognitive dysfunction (2021-2025).Frontiers in neurology · 2026Pooled it
- Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025Pooled it
- Association between COVID-19 infection and new-onset dementia in older adults: a systematic review and meta-analysis.BMC geriatrics · 2024Pooled it
- Healthcare resource use and costs following RSV-related hospitalizations among US adults aged 50 years and older.Human vaccines & immunotherapeutics · 2026Article
- Neurological Manifestations of Long COVID: Current Evidence, Emerging Concepts, and Future Perspectives.Journal of clinical medicine · 2026Review
- Low serum selenium combined with SELENOP-autoantibodies are associated with persistent fatigue after SARS-CoV-2 infection.Redox biology · 2026Article
- NeuroCOVID Burden and Functional Impairment in Adults with Long COVID: A Secondary Analysis of an Italian Cohort.Journal of clinical medicine · 2026Article
- Multi-organ structural and functional deficits in association with long COVID: a population-based case-control study.EClinicalMedicine · 2026Article
- Association of COVID-19 with risks of all-cause and cause-specific mortality post-infection: A UK Biobank cohort study.New microbes and new infections · 2026Article
- Increasing Incidence of Guillain-Barré Syndrome in the USA among Integrated Delivery Systems from 2017 to 2023: Trends by Age and Charlson Comorbidity Index Score.Neuroepidemiology · 2026Article
- Post-Acute Sequelae of COVID-19 Across 15 Major Health Domains and 67 Diseases in Individuals With Depressive Disorder: A Korean Nationwide Cohort Study.Journal of Korean medical science · 2026Article
- Neurocognitive and psychological symptoms in post COVID-19 patients (PASC24): prospective cohort study protocol.BMJ open · 2026Observational
- Effect of Long COVID-19: Self-Reported Questionnaires and Objective Olfactory and Gustatory Evaluations.Diseases (Basel, Switzerland) · 2026Article
- Neurological impairment in long COVID: implications for neurodegenerative disease.Journal of translational medicine · 2026Review
- Autoimmune diseases in the era of COVID-19: emerging mechanisms, clinical implications, vaccine considerations, and future directions.The Korean journal of internal medicine · 2026Review
- SARS-CoV-2 Infection, Vaccination Status, and Dementia Risk: A Nested Case-Control Study.Influenza and other respiratory viruses · 2026Article
- Understanding the long-term neurological effects of SARS-CoV-2 infection.Nature reviews. Neurology · 2026Review
- Modulation of Host Innate Immune Response by Highly Pathogenic Human Coronaviruses during Viral Infection.Journal of microbiology and biotechnology · 2026Review
- SARS-CoV-2 infection is associated with hypothalamic orexin suppression and persistent cortical NeuN attenuation.Journal of neuroinflammation · 2026Article
251 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neurologic manifestations of acute COVID-19 are well characterized, but a comprehensive evaluation of postacute neurologic sequelae at 1 year has not been undertaken. Here we use the national healthcare databases of the US Department of Veterans Affairs to build a cohort of 154,068 individuals with COVID-19, 5,638,795 contemporary controls and 5,859,621 historical controls; we use inverse probability weighting to balance the cohorts, and estimate risks and burdens of incident neurologic disorders at 12 months following acute SARS-CoV-2 infection. Our results show that in the postacute phase of COVID-19, there was increased risk of an array of incident neurologic sequelae including ischemic and hemorrhagic stroke, cognition and memory disorders, peripheral nervous system disorders, episodic disorders (for example, migraine and seizures), extrapyramidal and movement disorders, mental health disorders, musculoskeletal disorders, sensory disorders, Guillain-Barré syndrome, and encephalitis or encephalopathy. We estimated that the hazard ratio of any neurologic sequela was 1.42 (95% confidence intervals 1.38, 1.47) and burden 70.69 (95% confidence intervals 63.54, 78.01) per 1,000 persons at 12 months. The risks and burdens were elevated even in people who did not require hospitalization during acute COVID-19. Limitations include a cohort comprising mostly White males. Taken together, our results provide evidence of increased risk of long-term neurologic disorders in people who had COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.